- 期刊
Yun Zhi Polysaccharopeptide (PSP) and the General Aspects of Its Research
雲芝糖肽(PSP)及其研究概況
摘要
本文簡略介紹了雲芝糖肽(PSP)——一類新型的生物效應調節劑——的研究概況。PSP的生產原料為雲芝Cov-1菌株的深層培養菌絲體，由水提醇沉法分離而得，化學成份為結合蛋白多糖。經(上標 1)H、(上標 13)C核磁共振、GC-MS聯機及HPLC法等分析證明：PSP多糖中除含Glc.、Gla.、Man．和Xyl．外，另有Ara．和Rhm.，糖鏈中主含β1→3糖苷鍵、不同於日本PSK。 藥理學實驗證明，PSP能明顯拮抗由于負瘤或化療藥物引起的免疫抑制，阻斷胸腺萎縮，活化NK和LAK細胞，提高γ干擾素和IL-2、IL-6等的含量。毒理學研究證明，即使應用50-100倍臨床劑量，無論是急、慢性毒性；遺傳、生殖及二代致畸毒性試驗，PSP均與食用水相當。PSP能明顯毒殺肺癌(SPC)和肝癌(SMMV-7721)細胞，但對正常的肺細肫(V79)和肝細胞(QZG)未見明顯損害。經485例機雙盲法臨床研究證明：PSP能顯著改善胃、肺和食管患者的臨床證侯，降低化、放療毒副反應，提高生存質量，總有效率為82.96%。
並列摘要
This paper briefly introduces the general aspects of a new type biolobical response modifier—PSP. The production material of polysaccharopeptide (PSP) is the deep layer cultivated mycelia of Cov-1 strain of Yun Zhi isolated by the methol of water extraction and alcoholic precipitation. Its chemical components are protein-bound polysaccharides. After the analyses of (superscript 1) H, (superscript 13) C nuclear magentic resonance, GCMS on-line and HPLC analysis, it has been proved that the polysaccharopeptide contains Glc., Gla., Man., and Xy1. in addition to Ara. and Rahmose. In the polysaccharide of PSP, the main content is β1-3 glycosidic bond and it is different from that of Japanese Krestin (PSK). The pharmacology proves that PSP can obviously resist immune suppression caused by tumor-bearing or chemotherapy, prevent the atrophy of thymus, activate NK and LAK cells and incresse the contents of γ-interferon, IL-2, IL-6, etc. The toxicology proves that even administering 50-100 times the normal clinical dosage to patients, the toxicity of PSP is equivalent to that of ordinary drinking water, either in the cure of acute and chronic hepatitis, hereditary, reproductive and second generation teratogenic toxicity. PSP can obviously kill the SPS of lung cancer and SMMU-7721 of liver cancer cells and there is no obvious harm at all on V79 of lung cells and on GZG of liver cells. Through 485 cases of random double-blind clinical experiments, it has been proved that PSP can obviously improve the clinical symptoms of stomach, lung and esophagus cancer patients, lower the toxic and side effects of chemo- and radio-therapy and raise the life quality of patients. The total effective rate is 82.96%.